logo
Plus   Neg
Share
Email

Leoni 2019 Preliminary Sales Down

Leoni AG (LEOGN), a provider of energy and data management solutions in the automotive market, reported 2019 preliminary sales of 4.8 billion euros, lower than prior year's 5.1 billion euros.

EBIT before exceptional items as well as before VALUE 21 costs to report negative of 66 million euros versus 157 million euros last year.

The preliminary reported Group EBIT for full year was burdened by exceptional items as well as VALUE 21 costs amounting to 318 million euros resulting in reported EBIT to report negative of 384 million euros.

Based on current findings, the Executive Board decided that a provision for expected losses from an onerous contract of around 80 million euros is necessary. The formation of this provision impacted the result for the fourth quarter of 2019, the company stated.

The company also noted that the losses could become cash-effective in the course of 2021 and over a period of several years thereafter. In addition, non-cash write-downs of assets of 20 million euros impacted the divisional result of the Wire & Cable Solutions division.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) expects that its first-quarter operating profit will increase about 2.73 percent from last year, sales will also increase 4.98 percent. JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered.
Follow RTT
>